Arbutus Biopharma Corp. (NASDAQ:ABUS) shares shot up 3.5% on Friday . The stock traded as high as $3.84 and last traded at $3.81, with a volume of 65,485 shares traded. The stock had previously closed at $3.68.

Several research firms recently weighed in on ABUS. Leerink Swann restated a “buy” rating and issued a $12.00 price objective on shares of Arbutus Biopharma Corp. in a research report on Thursday, May 5th. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Arbutus Biopharma Corp. in a research report on Wednesday, May 4th. Chardan Capital cut shares of Arbutus Biopharma Corp. from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $3.25 to $2.75 in a research report on Friday, July 8th. Finally, Zacks Investment Research cut shares of Arbutus Biopharma Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Arbutus Biopharma Corp. has an average rating of “Hold” and an average price target of $9.79.

The firm’s market capitalization is $208.22 million. The company’s 50 day moving average is $3.95 and its 200 day moving average is $3.94.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.36. On average, equities analysts forecast that Arbutus Biopharma Corp. will post ($3.28) earnings per share for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.